Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study

Mette Søgaard1, Dóra Kőrmendiné Farkas1, Vera Ehrenstein1, Jens Otto Lunde Jørgensen2, Olaf M Dekkers1,3 and Henrik Toft Sørensen1

Departments of 1Clinical Epidemiology, 2Endocrinology and Internal Medicine (MEA), Aarhus University Hospital, Olof Palmes Allé 43-45, DK-8200 Aarhus N, Denmark and 3Departments of Endocrinology and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

Correspondence should be addressed to M Søgaard
Email mso@clin.au.dk

Abstract

Objective: The association between thyroid disease and breast cancer risk remains unclear. We, therefore examined the association between hypothyroidism, hyperthyroidism and breast cancer risk.

Design: This was a population-based cohort study.

Methods: Using nationwide registries, we identified all women in Denmark with a first-time hospital diagnosis of hypothyroidism or hyperthyroidism, 1978–2013. We estimated the excess risk of breast cancer among patients with hypothyroidism or hyperthyroidism compared with the expected risk in the general population, using standardized incidence ratios (SIRs) as a measure of risk ratio. Breast cancer diagnoses in the first 12 months following diagnosis of thyroid disease were excluded from the calculations to avoid diagnostic work-up bias.

Results: We included 61 873 women diagnosed with hypothyroidism and 80 343 women diagnosed with hyperthyroidism. Median follow-up time was 4.9 years (interquartile range (IQR): 1.8–9.5 years) for hypothyroidism and 7.4 years (IQR: 3.1–13.5 years) for hyperthyroidism. Hyperthyroidism was associated with a slightly increased breast cancer risk compared with the general population (SIR: 1.11, 95% CI: 1.07–1.16), which persisted beyond 5 years of follow-up (SIR: 1.13, 95% CI: 1.08–1.19). In comparison, hypothyroidism was associated with a slightly lower risk of breast cancer (SIR: 0.94, 95% CI: 0.88–1.00). Stratification by cancer stage at diagnosis, estrogen receptor status, age, comorbidity, history of alcohol-related disease and clinical diagnoses of obesity produced little change in cancer risk.

Conclusions: We found an increased risk of breast cancer in women with hyperthyroidism and a slightly decreased risk in women with hypothyroidism indicating an association between thyroid function level and breast cancer risk.

Introduction

Breast cancer is the most frequent cancer in females, with 458 337 new cases diagnosed in Europe in 2012 (1). Endogenous and exogenous sex hormones play an important role in the etiology of breast cancer (2). In vitro, high levels of thyroid hormones have estrogen-like effects (3, 4), promoting breast cancer cell proliferation (5, 6) and stimulating angiogenesis (7). Therefore, hyperthyroidism, characterized by increased levels of thyroid hormones, may potentially also increase breast cancer risk.

Epidemiological evidence concerning thyroid disorders and breast cancer risk remains unclear. Some epidemiological studies have reported increased risks associated with hypothyroidism (8, 9), hyperthyroidism (10, 11, 12), goiter (13) and thyroid autoimmune diseases (14, 15), while others have found no association (9, 16, 17, 18). Only four studies employed a cohort design (9, 11, 12, 15); in case–control studies, reverse causation is a plausible competing explanation since breast cancer or its treatment may affect thyroid hormone levels (19). Moreover, some studies have not distinguished between hypothyroidism and hyperthyroidism, despite their contrasting hormonal profiles (13, 16, 17). We conducted a
nationwide population-based cohort study in Denmark to examine the association between hypothyroidism, hyperthyroidism and risk of breast cancer.

**Subject and methods**

**Study setting**

In this nationwide population-based cohort study in Denmark we included data from 1 January 1978 to 31 November 2013. The Danish National Health Service guarantees tax-supported health care for all residents. Health service utilization is tracked by several nationwide registries, which are linkable using each resident’s universal personal identifier, assigned to all Danish residents at birth or upon immigration since 1968 (20). Our study’s source population consisted of the 4 177 429 women who resided in Denmark during the study period.

**Hypothyroidism and hyperthyroidism**

The Danish National Patient Registry (DNPR) contains information on all inpatient hospitalizations at Danish non-psychiatric hospitals since 1977 and outpatient and emergency department visits since 1995 (21, 22). Each hospital visit is recorded by physicians with one primary diagnosis and one or more secondary diagnoses classified according to the International Classification of Diseases, 8th edition (ICD-8) until the end of 1993, and ICD-10 thereafter. We used the DNPR to identify all women with a first-time diagnosis of hypothyroidism or hyperthyroidism from 1978 through 2013 (see Supplementary Table 1 for codes, see section on supplementary data given at the end of this article). Women with a diagnosis of hypothyroidism and hyperthyroidism on the same date \((n=481)\) were excluded, and women with hyperthyroidism who subsequently developed hypothyroidism \((n=8185)\) or vice versa \((n=1895)\) were censored on the date of the new diagnosis.

**Breast cancer**

To identify incident breast cancer cases, the cohorts of women with a diagnosis of hypothyroidism or hyperthyroidism were linked to the Danish Cancer Registry (DCR), which records all incident cancers in Denmark since 1943, with mandatory reporting since 1987 (23). We excluded women with a breast cancer diagnosis prior to the diagnosis of hypothyroidism or hyperthyroidism. Through the DCR, we also obtained data on breast cancer stage at diagnosis (classified according to Summary Staging as localized vs non-localized disease). We also performed a linkage to the Danish Pathology Registry (24) to retrieve data on estrogen receptor (ER) status at breast cancer diagnosis starting in 1997 (as pathology data became available in that year).

**Comorbid diseases**

We computed the Charlson Comorbidity Index (CCI) scores for each patient based on all available DNPR inpatient hospitalization records preceding the date of diagnosis of hypothyroidism or hyperthyroidism (25). We categorized severity of comorbidities as low (CCI score = 0), medium (CCI score = 1–2) or high (CCI score ≥ 3), excluding breast cancer diagnoses from the CCI score calculation. We also used the DNPR to access information on clinical diagnoses of obesity and alcohol-related disease (see Supplementary Table 1 for codes).

**Statistical analysis**

We followed women from the date of their first diagnosis of hypothyroidism or hyperthyroidism until incident breast cancer, death, emigration, or 31 November 2013, whichever came first. We computed the expected number of breast cancer cases using national incidence rates by age (5-year bands) and year of diagnosis (5-year periods) multiplied by person-years of follow-up. We computed standardized incidence ratios (SIRs) for breast cancer as the ratio of observed to expected cancers. Breast cancer diagnoses in the first 12 months following diagnosis of thyroid disease were excluded from the calculations to avoid overestimating the association by including prevalent occult breast cancers diagnosed during the diagnostic work-up for thyroid disease. Confidence intervals (CIs) for the SIRs were computed assuming that the observed number of cases in a specific category followed a Poisson distribution, using Byar’s approximation (26). We stratified results by age at diagnosis, calendar period, CCI score categories, hospital diagnoses of obesity and alcohol-related disease, breast cancer stage at diagnosis and ER status (for women diagnosed between 1997 and 2013). We also computed the absolute risk of breast cancer with death as a competing risk. The follow-up period was categorized as 1–5 years and >5 years. As radioactive iodine (RAI) treatment may increase breast cancer risk (27), we conducted a sensitivity analysis in which follow-up was censored at initiation of RAI treatment. Smoking is an established risk factor for Graves’ disease (28), we
therefore also conducted a sensitivity analysis excluding patients with Graves’ disease in order to reduce potential confounding by smoking. We restricted this analysis to 1994–2011, the period during which there was a specific code for Graves’ disease in the Danish ICD version (see Supplementary Table 1 for codes). Finally, we conducted a sensitivity analysis restricted to women who were diagnosed with hypothyroidism or hyperthyroidism starting in 1995 or later in order to capture information on outpatient diagnoses.

The study was approved by the Danish Data Protection Agency, record number 1-16-02-1-08. Studies based on registry data in Denmark do not require informed consent.

Results

There were 61,873 women diagnosed with hypothyroidism (median age at diagnosis: 71 years, interquartile range (IQR): 52–82 years) and 80,343 women diagnosed with hyperthyroidism (median age: 70 years, IQR: 55–82 years). Median follow-up was 4.9 years (IQR: 1.8–9.8 years) for patients with hypothyroidism and 7.4 years (IQR: 3.1–13.5 years) for patients with hyperthyroidism respectively. The proportion of women diagnosed with hypothyroidism increased substantially over time. In the calendar periods when outpatient diagnoses were available, 15.0% of hypothyroidism cases were diagnosed during 1998–2002, compared with 35.2% during 2008–2013 (Table 1). The corresponding percentages for hyperthyroidism were 20.4 and 20.6%. Most patients had no comorbidity requiring hospitalization at the time of diagnosis of hypothyroidism (65.8%) or hyperthyroidism (74.8%). Hospital diagnoses of obesity were more prevalent among women with hypothyroidism compared with hyperthyroidism (8.5 vs 3.5%). Less than 2% had a diagnosis of alcohol-related disease.

Overall, hyperthyroidism was associated with an increased risk of breast cancer (SIR: 1.11, 95% CI: 1.07–1.16), while hypothyroidism was associated with a slightly decreased risk of breast cancer (SIR: 0.94, 95% CI: 0.88–1.00) (Table 2). The hyperthyroidism-associated increased risk persisted beyond 5 years of follow-up (SIR: 1.13, 95% CI: 1.08–1.19). Stratification by cancer stage at diagnosis, ER status, age, comorbidity, history of alcohol-related disease and clinical diagnoses of obesity produced little change in breast cancer risk. Breast cancer risk in women with hyperthyroidism was unaffected by censoring at RAI treatment initiation (SIR: 1.08, 95% CI: 0.98–1.18, during 2002–2013) or by exclusion of patients with Graves’ disease (SIR: 1.09, 95% CI: 1.02–1.16, during 1994–2011).

Between 1995 and 2013, 48,363 women had a diagnosis of hypothyroidism, of which 20,225 (41.8%) were inpatient diagnoses and 28,138 (58.2%) were outpatient diagnoses. Over the same period, 56,877 women had a diagnosis of hyperthyroidism. Of these women, 19,532 (34.3%) had inpatient diagnoses and 37,345 (65.7%) had outpatient diagnoses. Restricting the study period to 1995–2013 produced the same overall SIR estimates as the main analysis (Supplementary Table 2, see section on supplementary data given at the end of this article). Stratification by inpatient vs outpatient diagnoses indicated a slightly higher breast cancer risk increase associated with outpatient diagnoses (SIR: 1.17, 95% CI: 1.06–1.29) of hyperthyroidism compared with inpatient diagnoses (SIR: 1.07, 95% CI: 0.94–1.22), particularly after 5 years of follow-up (Supplementary Table 2).

Discussion

This nationwide population-based cohort study spanning over a 30-year period revealed an elevated risk of breast cancer in women with hyperthyroidism, which increased with longer follow-up. Over the same period, women with
hypothyroidism experienced a slightly decreased risk of breast cancer.

During the last 50 years, several epidemiological studies have examined the association between thyroid disorders and the risk for breast cancer. Most of the previous studies examined the effect of thyroid hormone levels on breast cancer risk in a case–control setting (14, 16, 17, 29), in which reverse causation may be difficult to rule out. Our findings are in line with three of the earlier cohort studies that found an association between higher premorbid levels of thyroid hormone and breast cancer risk (11, 12, 15), while the fourth cohort study found an association between low levels of free thyroxine and an increased risk of breast cancer (9). The lack of increase in the risk of breast cancer in women with hypothyroidism, observed in this study, is also in agreement with the results of a recent meta-analysis of 12 observational studies showing no association between hypothyroidism and breast cancer risk (18).

Several biological processes may underlie the observed associations between thyroid diseases and breast cancer risk. In vitro studies have demonstrated a proliferative effect of triiodothyronine (T3, the active thyroid hormone) in the breast (5, 6). At the cellular level, T3 binds to high-affinity nuclear receptors and induces transcription of target genes involved in energy homeostasis and cell proliferation. In vitro studies suggest a critical role of these receptors in breast cancer development (5, 30, 31).

### Table 2


<table>
<thead>
<tr>
<th></th>
<th>Women with hypothyroidism</th>
<th></th>
<th>Women with hyperthyroidism</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of person-years</td>
<td>Observed/expected cancer</td>
<td>SIR (95% CI)</td>
</tr>
<tr>
<td>Overall</td>
<td>36 1640</td>
<td>970/1031</td>
<td>0.94 (0.88–1.00)</td>
</tr>
<tr>
<td>Age at diagnosis of thyroid disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;30 years</td>
<td>37 559</td>
<td>17/15</td>
<td>1.17 (0.68–1.88)</td>
</tr>
<tr>
<td>30–49 years</td>
<td>102 422</td>
<td>197/206</td>
<td>0.96 (0.83–1.10)</td>
</tr>
<tr>
<td>50–69 years</td>
<td>137 188</td>
<td>486/505</td>
<td>0.96 (0.88–1.05)</td>
</tr>
<tr>
<td>≥70 years</td>
<td>84 472</td>
<td>270/306</td>
<td>0.88 (0.78–0.99)</td>
</tr>
<tr>
<td>Calendar period of the diagnosis of thyroid disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1978–1982</td>
<td>35 984</td>
<td>95/95</td>
<td>1.00 (0.81–1.23)</td>
</tr>
<tr>
<td>1983–1987</td>
<td>3292</td>
<td>79/92</td>
<td>0.85 (0.68–1.06)</td>
</tr>
<tr>
<td>1988–1992</td>
<td>41 069</td>
<td>145/122</td>
<td>1.19 (1.00–1.40)</td>
</tr>
<tr>
<td>1993–1997</td>
<td>63 914</td>
<td>181/188</td>
<td>0.96 (0.83–1.11)</td>
</tr>
<tr>
<td>1998–2002</td>
<td>76 474</td>
<td>194/223</td>
<td>0.87 (0.75–1.00)</td>
</tr>
<tr>
<td>2003–2007</td>
<td>76 232</td>
<td>191/221</td>
<td>0.87 (0.75–1.00)</td>
</tr>
<tr>
<td>2008–2013</td>
<td>35 045</td>
<td>85/89</td>
<td>0.95 (0.76–1.18)</td>
</tr>
<tr>
<td>Charlson comorbidity index score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low (0)</td>
<td>273 988</td>
<td>706/746</td>
<td>0.95 (0.88–1.02)</td>
</tr>
<tr>
<td>Moderate (1–2)</td>
<td>75 678</td>
<td>217/242</td>
<td>0.90 (0.78–1.02)</td>
</tr>
<tr>
<td>High (≥3)</td>
<td>11 974</td>
<td>47/42</td>
<td>1.12 (0.82–1.49)</td>
</tr>
<tr>
<td>Obesity diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>337 465</td>
<td>918/963</td>
<td>0.95 (0.89–1.02)</td>
</tr>
<tr>
<td>Yes</td>
<td>24 175</td>
<td>52/68</td>
<td>0.77 (0.57–1.01)</td>
</tr>
<tr>
<td>Alcohol-related disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>354 797</td>
<td>943/1010</td>
<td>0.93 (0.88–1.00)</td>
</tr>
<tr>
<td>Yes</td>
<td>6842</td>
<td>27/21</td>
<td>1.30 (0.86–1.89)</td>
</tr>
<tr>
<td>Breast cancer stage at diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Localized</td>
<td>361 640</td>
<td>467/491</td>
<td>0.95 (0.87–1.04)</td>
</tr>
<tr>
<td>Non-localized</td>
<td>361 640</td>
<td>377/427</td>
<td>0.88 (0.80–0.98)</td>
</tr>
<tr>
<td>Unknown stage</td>
<td>361 640</td>
<td>126/113</td>
<td>1.11 (0.93–1.32)</td>
</tr>
<tr>
<td>ER status‡</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER negative</td>
<td>200 431</td>
<td>67/77</td>
<td>0.87 (0.67–1.10)</td>
</tr>
<tr>
<td>ER positive</td>
<td>200 431</td>
<td>387/423</td>
<td>0.91 (0.83–1.01)</td>
</tr>
<tr>
<td>Missing ER status</td>
<td>200 431</td>
<td>55/70</td>
<td>0.78 (0.59–1.02)</td>
</tr>
<tr>
<td>Length of follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–5 years</td>
<td>161 183</td>
<td>390/424</td>
<td>0.92 (0.83–1.02)</td>
</tr>
<tr>
<td>&gt;5 years</td>
<td>200 457</td>
<td>580/607</td>
<td>0.96 (0.88–1.04)</td>
</tr>
</tbody>
</table>

In contrast to the experimental evidence that T₃ and estrogen synergistically stimulate certain breast cancer cell lines (3, 4, 6, 32), in our study, the association between hyperthyroidism and breast cancer risk was not modified by ER status.

We conducted a large nationwide population-based cohort study, with complete follow-up and highly valid data for thyroid disease (21, 23, 33) and breast cancer diagnoses (34, 35). The higher incidence of hyperthyroidism compared with hypothyroidism is in agreement with previous studies (36), as is the increased incidence of thyroid disease over time (37). One contributing factor to the higher incidence in hyperthyroidism is the fact that before 1995 only inpatient diagnosis were recorded in the DNPR (21), and hyperthyroidism is more likely than hypothyroidism to be diagnosed and treated in an inpatient setting as also shown in our study. However, a sensitivity analysis restricted to patients diagnosed from 1995 onward and stratified by inpatient vs outpatient diagnoses, yielded similar findings. A limitation of our study was the lack of laboratory data. We were therefore unable to distinguish between clinical and subclinical thyroid disease, as we were also unable to link the hormone levels at time of diagnosis to breast cancer risk. Of note, the exposure window in hyperthyroidism is short, as the hyperthyroid state is rapidly diagnosed, and ensuing treatment normalizes thyroid levels within a few weeks (38). Finally, the observed association between hyperthyroidism and breast cancer risk may have been underestimated due to incompletely ascertainment (and therefore not adjusted for) lifestyle risk factors for breast cancer, such as obesity and alcohol consumption, both of which are associated with a reduced risk of hyperthyroidism (28, 39) but an increased risk of breast cancer (40).

We stratified our analyses by hospital diagnoses of obesity and alcohol-related illness, however, these diagnoses are likely to capture only the most severe cases. Smoking has been associated with an increased risk of Graves’ disease (28), but has no consistent association with breast cancer risk (41), and exclusion of patients with Graves’ disease did not change our estimates. Finally, we did not address the role of hormonal treatment in the observed association. The role of treatment should be explored in further studies.

In conclusion, we found an increased risk of breast cancer in women with hyperthyroidism and a slightly decreased risk in women with hypothyroidism suggesting an association between the thyroid function level and breast cancer risk.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-15-0989.

Declaration of interest
The authors report no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by the Program for Clinical Research Infrastructure (PROCRIN), established by the Lundbeck and the Novo Nordisk Foundations; by the Danish Cancer Society (R73-A4284-13-517); and by the Aarhus University Research Foundation.

References
11 Hellekvik AI, Asvold BO, Bjoro T, Romundstad PR, Nilsen TIL & Vatten LJ. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiology, Biomarkers and Prevention 2009 18 570–574. (doi:10.1158/1055-9965.EPI-08-0911)
13 Smyth PP, Smith DF, McDermott EW, Murray MJ, Geraghty JG & O’Higgins NJ. A direct relationship between thyroid enlargement and


29 Cristofanilli M, Yamamura Y, Kau S, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Therault RL & Hortobagyi GN. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. *Cancer* 2005 **103** 1122–1126. (doi:10.1002/cncr.20881)


33 Vestergaard P & Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. *Thyroid* 2002 **12** 411–419. (doi:10.1089/105072502760043505)


38 Vaidya B & Pearce SH. Diagnosis and management of thyrotoxicosis. *BMJ* 2014 **349** g5128. (doi:10.1136/bmj.g5128)


Received 6 October 2015
Revised version received 23 November 2015
Accepted 19 January 2016